Sign In
Buy AVDL
$21.64
+0 (+0%)
At Close: May 08, 2026
Avadel: Mispriced Leader In Once-Nightly Sleep Therapies
05:20am, Tuesday, 30'th Sep 2025
Avadel Pharmaceuticals is deeply undervalued, with LUMRYZ and Valiloxybate offering $2B+ peak sales potential in sleep disorders. AVDL's once-at-bedtime Oxybate franchise is clinically superior, paten
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
08:00am, Tuesday, 16'th Sep 2025
A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept.
Avadel: LUMRYZ Momentum And Pipeline Expansion Support Buy Rating
03:29am, Friday, 12'th Sep 2025
Avadel's stellar 2024 performance is driven by LUMRYZ's strong revenue growth, positive net income, and robust patient demand. The $20M global licensing deal for valiloxybate diversifies Avadel's pipe
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 10'th Sep 2025
DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of
Avadel Pharmaceuticals Plc (AVDL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
04:24pm, Tuesday, 09'th Sep 2025
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Thomas McHugh - Senior VP, Principal Financial & Ac
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025
08:00am, Friday, 05'th Sep 2025
– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates �
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
04:30pm, Wednesday, 03'rd Sep 2025
– Expands Avadel's pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia –
Does Avadel (AVDL) Have the Potential to Rally 27.95% as Wall Street Analysts Expect?
10:55am, Wednesday, 27'th Aug 2025
The mean of analysts' price targets for Avadel (AVDL) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
Wall Street Analysts Predict a 37.25% Upside in Avadel (AVDL): Here's What You Should Know
10:55am, Monday, 11'th Aug 2025
The consensus price target hints at a 37.3% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Avadel Pharmaceuticals plc (AVDL) Q2 2025 Earnings Call Transcript
01:45am, Friday, 08'th Aug 2025
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Gregory J. Divis - CEO & Director Susan Rodriguez - Chief Operating Officer Th
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 07'th Aug 2025
DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance
07:00am, Thursday, 07'th Aug 2025
-- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of Jun
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
08:00am, Thursday, 31'st Jul 2025
DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 21'st Jul 2025
DUBLIN, July 21, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of
ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders
07:00am, Monday, 14'th Jul 2025
GREENWICH, Conn. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--ASL Strategic Value Fund, LP (together with its affiliates, “ASL Strategic Value Fund” or “we”), a significant shareholder of Avadel Phar
